Corvidane: Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

1

CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.

2

Corvidane raised $360k from over 200 Investors in previous RegCF.

3

Corvidane granted ~$700k in non-dilutive grants for Research and Development.

4

Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.

5

Corvida™ is protected by patents in the US, Japan and Brazil and are owned by the company.

6

Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.

7

Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.

8

This is an opportunity to impact global health and potentially realize significant financial gains.

Paresh SoniCEO

20+ years of executive pharmaceutical experience in Cardiovascular diseases and NASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.

Damion Boyer

Co-Founder / COO

6 years experience as CEO of Corvidane. Responsible for initiating Corvidane’s NASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.

Patrice BINAY

VP of Chemistry and CMC

32 years of pharmaceutical Fine Chemistry experience. Synthesis and analytical characterization of Active Pharmaceutical Ingredients, Quality auditing, Industrial Transfer. Development of a new class of anti-inflammatory (H4 Receptor).

Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

$366,884

Highlights

Our Team

Pitch